Lantern Pharma Announces Scientific & Preclinical Data Indicating Blood Brain Permeability for Drug Candidate LP-184 in Glioblastoma and Potentially Other CNS Cancers

By |2020-12-15T16:52:47+00:00December 15th, 2020|

Lantern Pharma Announces Scientific & Preclinical Data Indicating Blood Brain Permeability for Drug Candidate LP-184 in Glioblastoma and Potentially Other CNS Cancers Dec 15, 2020, 07:00 ET Read on Cision PR Newswire LP-184 preclinical studies reinforce the drug compound’s potential to effectively cross the blood-brain barrier with significant potency Continued progress in advancing glioblastoma [...]

Lantern Pharma Advances Prostate Cancer Drug Development Research Collaboration with Georgetown University for LP-184, a Next-Generation, Targeted DNA-Damaging Agent

By |2020-10-05T15:46:33+00:00October 5th, 2020|

Lantern Pharma Advances Prostate Cancer Drug Development Research Collaboration with Georgetown University for LP-184, a Next-Generation, Targeted DNA-Damaging AgentOct 05, 2020, 07:46 ETRead on Cision PR NewswireDALLAS, Oct. 5, 2020 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to improve drug discovery and development, and identify patients who will benefit [...]